Comparison of Species and Cell-Type Differences in Fraction Unbound of Liver Tissues, Hepatocytes, and Cell Lines
Open Access
- 2 February 2018
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 46 (4), 415-421
- https://doi.org/10.1124/dmd.117.079152
Abstract
Fraction unbound (fu) of liver tissue, hepatocytes, and other cell types is an essential parameter used to estimate unbound liver drug concentration and intracellular free drug concentration. fu,liver and fu,cell are frequently measured in multiple species and cell types in drug discovery and development for various applications. A comparison study of 12 matrices for fu,liver and fu,cell of hepatocytes in five different species (mouse, rat, dog, monkey, and human), as well as fu,cell of Huh7 and human embryonic kidney 293 cell lines, was conducted for 22 structurally diverse compounds with the equilibrium dialysis method. Using an average bioequivalence approach, our results show that the average difference in binding to liver tissue, hepatocytes, or different cell types was within 2-fold of that of the rat fu,liver. Therefore, we recommend using rat fu,liver as a surrogate for liver binding in other species and cell types in drug discovery. This strategy offers the potential to simplify binding studies and reduce cost, thereby enabling a more effective and practical determination of fu for liver tissues, hepatocytes, and other cell types. In addition, fu under hepatocyte stability incubation conditions should not be confused with fu,cell, as one is a diluted fu and the other is an undiluted fu. Cell density also plays a critical role in the accurate measurement of fu,cell.Keywords
This publication has 21 references indexed in Scilit:
- Prediction of intracellular exposure bridges the gap between target- and cell-based drug discoveryProceedings of the National Academy of Sciences of the United States of America, 2017
- A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modelingJournal of Pharmacokinetics and Pharmacodynamics, 2014
- Rapid Measurement of Intracellular Unbound Drug ConcentrationsMolecular Pharmaceutics, 2013
- Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetesExpert Opinion on Drug Discovery, 2013
- Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and DyslipidemiaJournal of Medicinal Chemistry, 2011
- Species Independence in Brain Tissue Binding Using Brain HomogenatesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2011
- Impact of Nonspecific Binding to Microsomes and Phospholipid on the Inhibition of Cytochrome P4502D6: Implications for Relating in Vitro Inhibition Data to in Vivo Drug InteractionsDrug Metabolism and Disposition, 2003
- Cooperation of Liver Cells in Health and DiseasePublished by Springer Science and Business Media LLC ,2001
- Effect of temperature on membrane potential and ionic fluxes in intact and dialysed barnacle muscle fibresThe Journal of Physiology, 1972
- Ionic permeability changes as the basis of the thermal dependence of the resting potential in barnacle muscle fibresThe Journal of Physiology, 1972